What initial dose of insulin glargine (Lantus) is appropriate for a 70‑kg adult patient who is taking metformin 1 g twice daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Initial Insulin Glargine Dosing for Type 2 Diabetes on Metformin

For a 70-kg adult with type 2 diabetes already taking metformin 1 g twice daily, start insulin glargine (Lantus) at 10 units once daily OR 0.2 units/kg/day (14 units for this patient), administered at the same time each day. 1, 2

Recommended Starting Dose

The 2025 ADA Standards of Care explicitly recommend 10 units per day OR 0.1-0.2 units/kg per day for basal insulin initiation in type 2 diabetes 1. The FDA label for Lantus confirms 10 units or 0.2 units/kg once daily as the recommended starting dose for insulin-naive type 2 diabetes patients 2.

For your 70-kg patient, this translates to:

  • Conservative approach: 10 units daily (fixed dose)
  • Weight-based approach: 14 units daily (0.2 units/kg × 70 kg)

Both are acceptable starting points. The weight-based approach may achieve target faster but carries no additional hypoglycemia risk when combined with metformin 3.

Key Administration Details

  • Timing: Administer once daily at the same time every day (bedtime or morning—patient's choice for consistency) 2
  • Continue metformin: Keep the current metformin 1 g twice daily regimen 1, 4
  • Injection site: Rotate within the same region (abdomen, thigh, or deltoid) 2

Titration Strategy

After initiating, follow this evidence-based algorithm 1:

  1. Set fasting plasma glucose (FPG) goal: Typically 80-130 mg/dL for most adults
  2. Titration schedule: Increase by 2 units every 3 days until FPG goal is reached without hypoglycemia
  3. For hypoglycemia: If it occurs without clear cause, reduce dose by 10-20%
  4. Monitor: Check fasting blood glucose daily during titration

Evidence Supporting This Approach

The combination of basal insulin glargine with metformin is particularly effective and safe 4, 5. A landmark 2005 study demonstrated that adding once-daily glargine to metformin (with sulfonylurea) achieved superior HbA1c reduction (-1.64%) with significantly fewer hypoglycemic episodes (4.07 vs 9.87 events/patient-year) compared to premixed insulin 4.

More recent evidence from 2020 showed that even a higher starting dose of 0.3 units/kg in overweight/obese patients was safe, with only 11% experiencing confirmed hypoglycemia and zero severe hypoglycemia events 3. This suggests the standard 0.2 units/kg dose carries minimal hypoglycemia risk when combined with metformin.

Common Pitfalls to Avoid

  • Do NOT administer intravenously or via insulin pump—subcutaneous only 2
  • Do NOT mix or dilute Lantus with any other insulin or solution 2
  • Do NOT underdose initially: Starting too conservatively (e.g., 0.1 units/kg) delays glycemic control without meaningful safety benefit when metformin is continued 3
  • Do NOT discontinue metformin: The combination provides better glycemic control with less hypoglycemia and weight gain than insulin alone 4, 5

Why This Combination Works

Adding basal insulin to metformin monotherapy early in treatment provides superior efficacy/safety benefits 5. Metformin reduces insulin requirements, limits weight gain, and decreases hypoglycemia risk—making it the ideal partner for basal insulin initiation 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.